Piramal Pharma receives USFDA EIR for US facility; inspection ends with VAI
Piramal Pharma Ltd. on Monday, April 13, said the US Food and Drug Administration (USFDA) has issued an Establishment Inspection Report (EIR) for its manufacturing facility in Lexington, Kentucky, marking the successful closure of a recent inspection. The company said the inspection concluded with a Voluntary Action Indicated (VAI) status, indicating that while certain observations…
